Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver ...
Explore how digital feedback controllers manage motors, pressure, temperature, and more, and learn why ADC and DAC performance are crucial when designing robust embedded systems. How to define the ...
GlobalData on MSN
Turbine and AstraZeneca partner for ADC discovery
Turbine and AstraZeneca have entered a partnership to enhance the discovery of antibody-drug conjugates (ADCs) using the ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK ...
BigHat's next-gen ADC was optimized on BigHat's Milliner platform for maximum payload delivery to tumor cells and optimal drug-like-properties. The incorporation of Synaffix's GlycoConnect™, ...
Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback